We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$309M
AUM Growth
+$30.5M
Cap. Flow
+$16.2M
Cap. Flow %
5.24%
Top 10 Hldgs %
34.98%
Holding
101
New
36
Increased
15
Reduced
14
Closed
32

Top Buys

1
BIIB icon
Biogen
BIIB
+$12M
2
ENDP
Endo International plc
ENDP
+$10.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$10.1M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$8.63M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$7.56M

Top Sells

1
ZBH icon
Zimmer Biomet
ZBH
+$11.8M
2
CYH icon
Community Health Systems
CYH
+$7.84M
3
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$6.94M
4
CELG
Celgene Corp
CELG
+$6.92M
5
DYAX
DYAX CORPORATION
DYAX
+$5.86M

Sector Composition

1 Healthcare 85.5%
2 Financials 1.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
26
uniQure
QURE
$2.77B
$5M 1.62%
+185,000
New +$5.27M
GI
27
DELISTED
EndoChoice Holdings, Inc.
GI
$4.91M 1.59%
+300,000
New +$4.99M
PTCT icon
28
PTC Therapeutics
PTCT
$6.52B
$4.81M 1.56%
100,000
+40,000
+67% +$2.33M
CLLS
29
Cellectis
CLLS
$265M
$4.51M 1.46%
+125,000
New +$4.39M
VNDA icon
30
Vanda Pharmaceuticals
VNDA
$327M
$4.44M 1.44%
+350,000
New +$3.77M
ZLTQ
31
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$4.42M 1.43%
150,000
-75,000
-33% -$2.26M
CYNA
32
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$4.28M 1.39%
+262,696
New +$4.31M
IRWD icon
33
Ironwood Pharmaceuticals
IRWD
$635M
$4.22M 1.37%
+417,900
New +$4.86M
SAGE
34
DELISTED
Sage Therapeutics
SAGE
$4.2M 1.36%
57,500
-62,500
-52% -$4.02M
VTAE
35
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$4.16M 1.35%
289,200
-10,800
-4% -$147K
WMGI
36
DELISTED
Wright Medical Group Inc
WMGI
$3.94M 1.28%
150,000
-50,000
-25% -$1.32M
ARCT icon
37
Arcturus Therapeutics
ARCT
$172M
$3.92M 1.27%
85,714
-28,572
-25% -$1.31M
VIRX
38
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.76M 1.22%
5,952
-2,381
-29% -$1.27M
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.71M 1.2%
33,750
-18,750
-36% -$1.74M
ASMB icon
40
Assembly Biosciences
ASMB
$531M
$3.37M 1.09%
14,583
+4,166
+40% +$804K
ELV icon
41
Elevance Health
ELV
$80.9B
$3.28M 1.06%
+20,000
New +$3.2M
RMTI icon
42
CALL
Rockwell Medical
RMTI
$24.2M
$3.22M 1.04%
+1,818
New +$2.31M
ZVRA icon
43
Zevra Therapeutics
ZVRA
$755M
$3.21M 1.04%
+10,938
New +$2.39M
IOVA icon
44
Iovance Biotherapeutics
IOVA
$2.23B
$3.21M 1.04%
350,000
+150,000
+75% +$1.67M
TXMD icon
45
TherapeuticsMD
TXMD
$23.8M
$3.14M 1.02%
8,000
-4,000
-33% -$1.41M
SIOX
46
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$2.75M 0.89%
+16,875
New +$2.86M
FOMX
47
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.56M 0.83%
+250,000
New +$2.76M
ADVM
48
CALL
DELISTED
Adverum Biotechnologies
ADVM
$2.44M 0.79%
15,000
+5,000
+50% +$1.69M
BDSI
49
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.39M 0.77%
+300,000
New +$2.58M
SAGE
50
CALL
DELISTED
Sage Therapeutics
SAGE
$2.31M 0.75%
+31,700
New +$2.04M
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Ghost Tree Capital held 101 positions worth $309M, up 11% from $278M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ghost Tree Capital deployed $16.2M of net new capital in Q2 2015, opening 36 new positions and adding to 15 existing holdings. Its largest new stake was Biogen: 30,000 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 72% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Sage Therapeutics, an estimated $4.02M trimmed.

  • Ghost Tree Capital's largest Q2 2015 buy was Biogen: 30,000 shares worth $12.1M.
  • Ghost Tree Capital added most to Five Prime Therapeutics, Inc. in Q2 2015, an estimated $7.24M increase.
  • Ghost Tree Capital's biggest Q2 2015 reduction was Sage Therapeutics, cutting an estimated $4.02M.
  • Ghost Tree Capital fully exited Zimmer Biomet in Q2 2015, selling an estimated $11.8M.
  • Ghost Tree Capital's ten largest holdings make up 35% of its $309M portfolio in Q2 2015.
  • Ghost Tree Capital opened 36 new positions and closed 32 in Q2 2015.
  • Ghost Tree Capital's portfolio value rose 11% quarter-over-quarter to $309M.

Based on Ghost Tree Capital's 13F filing for Q2 2015, filed 14 Aug 2015.